Rocket Pharma Reports Patient Death In Rare Disease Gene Therapy Trial, FDA Puts Clinical Hold
1. RCKT's RP-A501 gene therapy faced a Serious Adverse Event resulting in patient death. 2. The FDA placed a clinical hold on RP-A501's Phase 2 trial pending review. 3. RCKT reports sufficient funding to operate into 2027, despite ongoing challenges. 4. Previous studies showed RP-A501 was generally well tolerated with positive efficacy data. 5. RCKT stock dropped 64.3% to $2.24 in the latest trading session.